PeptiDream Inc.

TSE:4587 Stock Report

Market Cap: JP¥128.1b

PeptiDream Valuation

Is 4587 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of 4587 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: 4587 (¥1025.5) is trading below our estimate of future cash flow value (¥3168.35)

Significantly Below Future Cash Flow Value: 4587 is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4587?

Key metric: As 4587 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 4587. This is calculated by dividing 4587's market cap by their current revenue.
What is 4587's PS Ratio?
PS Ratio6.9x
SalesJP¥19.05b
Market CapJP¥128.15b

Price to Sales Ratio vs Peers

How does 4587's PS Ratio compare to its peers?

The above table shows the PS ratio for 4587 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.1x
2160 GNI Group
5.2x23.38%JP¥140.5b
219A Heartseed
11.6x40.96%JP¥35.1b
7774 Japan Tissue Engineering
11.3xn/aJP¥24.7b
2929 Pharma Foods International
0.2x4.59%JP¥15.6b
4587 PeptiDream
6.9x17.46%JP¥131.8b

Price-To-Sales vs Peers: 4587 is good value based on its Price-To-Sales Ratio (6.9x) compared to the peer average (7.1x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does 4587's PS Ratio compare vs other companies in the JP Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
4974 Takara Bio
3.4xn/aUS$858.49m
7777 3-D Matrix
3.9xn/aUS$259.70m
2929 Pharma Foods International
0.2x4.59%US$96.49m
4584 Kidswell Bio
1x1.15%US$41.76m
4587 6.9xIndustry Avg. 13.0xNo. of Companies6PS020406080100+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 4587 is good value based on its Price-To-Sales Ratio (6.9x) compared to the JP Biotechs industry average (13x).

Price to Sales Ratio vs Fair Ratio

What is 4587's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4587 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.9x
Fair PS Ratio2x

Price-To-Sales vs Fair Ratio: 4587 is expensive based on its Price-To-Sales Ratio (6.9x) compared to the estimated Fair Price-To-Sales Ratio (2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4587 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentJP¥1,025.50
JP¥2,825.00
+175.48%
28.97%JP¥4,400.00JP¥1,600.00n/a6
Jun ’27JP¥1,047.50
JP¥2,825.00
+169.69%
28.97%JP¥4,400.00JP¥1,600.00n/a6
May ’27JP¥1,167.00
JP¥2,825.00
+142.07%
28.97%JP¥4,400.00JP¥1,600.00n/a6
Apr ’27JP¥1,250.00
JP¥2,825.00
+126.00%
28.97%JP¥4,400.00JP¥1,600.00n/a6
Mar ’27JP¥1,425.50
JP¥3,008.33
+111.04%
20.72%JP¥4,400.00JP¥2,700.00n/a6
Feb ’27JP¥1,564.00
JP¥3,033.33
+93.95%
20.56%JP¥4,400.00JP¥2,600.00n/a6
Jan ’27JP¥1,656.50
JP¥3,033.33
+83.12%
20.56%JP¥4,400.00JP¥2,600.00n/a6
Dec ’26JP¥1,731.00
JP¥3,328.57
+92.29%
22.92%JP¥4,900.00JP¥2,500.00n/a7
Nov ’26JP¥1,559.50
JP¥3,414.29
+118.93%
20.74%JP¥4,900.00JP¥2,500.00n/a7
Oct ’26JP¥1,521.50
JP¥3,414.29
+124.40%
20.74%JP¥4,900.00JP¥2,500.00n/a7
Sep ’26JP¥1,530.00
JP¥3,414.29
+123.16%
20.74%JP¥4,900.00JP¥2,500.00n/a7
Aug ’26JP¥1,671.50
JP¥3,542.86
+111.96%
17.06%JP¥4,900.00JP¥2,800.00n/a7
Jul ’26JP¥1,622.50
JP¥3,542.86
+118.36%
17.06%JP¥4,900.00JP¥2,800.00n/a7
Jun ’26JP¥1,754.00
JP¥3,542.86
+101.99%
17.06%JP¥4,900.00JP¥2,800.00JP¥1,047.507
May ’26JP¥1,984.00
JP¥3,542.86
+78.57%
17.06%JP¥4,900.00JP¥2,800.00JP¥1,167.007
Apr ’26JP¥2,145.50
JP¥3,557.14
+65.80%
16.92%JP¥4,900.00JP¥2,800.00JP¥1,250.007
Mar ’26JP¥2,035.50
JP¥3,471.43
+70.54%
17.81%JP¥4,900.00JP¥2,800.00JP¥1,425.507
Feb ’26JP¥2,146.00
JP¥3,442.86
+60.43%
18.43%JP¥4,900.00JP¥2,700.00JP¥1,564.007
Jan ’26JP¥2,644.50
JP¥3,442.86
+30.19%
18.43%JP¥4,900.00JP¥2,700.00JP¥1,656.507
Dec ’25JP¥2,941.50
JP¥3,442.86
+17.04%
18.43%JP¥4,900.00JP¥2,700.00JP¥1,731.007
Nov ’25JP¥2,700.00
JP¥3,350.00
+24.07%
19.94%JP¥4,900.00JP¥2,700.00JP¥1,559.507
Oct ’25JP¥2,729.00
JP¥3,342.86
+22.49%
20.03%JP¥4,900.00JP¥2,700.00JP¥1,521.507
Sep ’25JP¥2,560.00
JP¥3,366.67
+31.51%
21.40%JP¥4,900.00JP¥2,700.00JP¥1,530.006
Aug ’25JP¥2,690.00
JP¥3,250.00
+20.82%
24.54%JP¥4,900.00JP¥2,500.00JP¥1,671.506
Jul ’25JP¥2,423.00
JP¥2,883.33
+19.00%
34.88%JP¥4,900.00JP¥1,900.00JP¥1,622.506
Jun ’25JP¥1,969.00
JP¥2,850.00
+44.74%
35.01%JP¥4,900.00JP¥1,900.00JP¥1,754.006
JP¥2.83k
Fair Value
63.7% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/26 16:23
End of Day Share Price 2026/06/26 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PeptiDream Inc. is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shan HeBernstein
Hidemaru YamaguchiCitigroup Inc
Kazuaki HashiguchiDaiwa Securities Co. Ltd.